In adults, analysis of H(2) antagonist, motility agents and conservative treatment for GORD was not possible (lack of data) and there were no controlled studies of fundoplication. A single RCT in infants found that PPI (compared to placebo) was not efficacious for cough outcomes (favouring placebo OR 1.61 95% CI 0.57 to 4.55) but those on PPI had significantly increased adverse events (OR 5.56 95% CI 1.18 to 26.25) (number needed to treat for harm in four weeks was 11 (95% CI 3 to 232)).
None of the paediatric studies could be combined for meta-analysis. We included 19 studies (six paediatric, 13 adults). We contacted study authors for further information.
Two review authors independently assessed trial quality and extracted data. The date of last search was 8 April 2010.Īll randomised controlled trials (RCTs) on GORD treatment for cough in children and adults without primary lung disease. We searched the Cochrane Airways Group Specialised Register, the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, review articles and reference lists of relevant articles. To evaluate the efficacy of GORD treatment on chronic cough in children and adults with GORD and prolonged cough that is not related to an underlying respiratory disease, i.e. Treatment for GORD includes conservative measures (diet manipulation), pharmaceutical therapy (motility or prokinetic agents, H(2)-antagonist and proton pump inhibitors (PPI)) and fundoplication. Gastroesophageal reflux disease (GORD) is said to be the causative factor in up to 41% of adults with chronic cough.